Tumour molecular subtyping according to hormone receptors and HER2 status defines different pathological complete response to neoadjuvant chemotherapy in patients with locally advanced breast cancer

Abstract

Tumour molecular subtyping defines different pCR to neoadjuvant chemotherapy (NC) but has no impact over DFS in patients with LABC. Although no significant correlation between HER2 status and trastuzumab therapy with pCR was found, probably due to the small number of patients, a favourable trend was observed in the group of HER2+ tumours treated with T.

Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists

“…As to treatment response, 17-58% of patients with triple-negative breast cancers have been shown to have a pathological complete response after anthracycline-or anthracycline þ taxane-based neoadjuvant chemotherapy 25,28,122,123 and 17% of triplenegative cancers have been shown to have a pathological complete response after neoadjuvant platinum-based chemotherapy. 124 However, those who fail to achieve pathological complete response have a dismal outcome.…”

Triple-negative invasive breast cancer on dynamic contrast-enhanced and diffusion-weighted MR imaging: comparison with other breast cancer subtypes

“…HER2-positive; ER and PR may be positive or negative), and ER-positive (i.e. ERpositive, HER2-negative, PR may be positive or negative) types [9,10]. These immunohistochemical subtypes correspond roughly to the molecular subtypes of basal-like, HER2-positive and luminal, respectively [2].…”

Tumour 18 F-FDG Uptake on preoperative PET/CT may predict axillary lymph node metastasis in ER-positive/HER2-negative and HER2-positive breast cancer subtypes

“…Immunohistochemical (IHC) classification based on expression of the oestrogen receptor (ER), the progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) is the most frequently used molecular marker in clinical practice and is valuable in predicting the clinical outcome as well as guiding targeted treatments [8]. IHC classification categorizes breast tumours into three major tumour subtypes: ER-positive (i.e., ER positive, HER2 negative, PR may be positive or negative), HER2-positive (i.e., HER2 positive; ER and PR may be positive or negative), and triple-negative (i.e., ER negative, PR negative and HER2 negative) [9,10]; these correspond roughly to the intrinsic molecular subtypes of luminal, HER2-positive, and basal-like forms, respectively [11]. 18 F-fluorodeoxyglucose positron emission tomography/ computed tomography ( 18 F-FDG PET/CT) is becoming increasingly important in the diagnosis and management of patients with breast cancer [12][13][14].…”